X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Pacific Biosciences Begins Shipments of Commercial PacBio RS Systems

Wednesday, April 27, 2011

World’s First Single Molecule, Real-Time System Inaugurates New Era

of Third Generation DNA Sequencing

MENLO PARK, Calif.–(BUSINESS WIRE)–

Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced

it is now shipping commercial PacBio RS systems. The release of

the first “third generation” sequencing product is expected to

immediately expand the applications of DNA sequencing in fields such as

cancer research, pathogen detection, and agriculture. These commercial

shipments are following a successful early access program conducted with

eleven leading sequencing customers around the world.

The PacBio RS is a third-generation DNA sequencing instrument system that conducts, monitors, and analyzes single molecule sequencing reactions in real time. (Photo: Business Wire)

The PacBio RS is a revolutionary DNA sequencing system that

incorporates novel, single molecule sequencing techniques and advanced

analytics to reveal biology in real time. The system delivers

unprecedented sequence readlengths over a thousand DNA bases on

average. And unlike “second generation” systems on the market today that

typically take over one week to deliver results, the PacBio RS

allows customers to obtain results in less than a day.

The first commercial units are being shipped to sites in North America

and Europe that include biotechnology companies, commercial service

providers, governmental institutions, and academic laboratories. The

National Biodefense Analysis and Countermeasures Center (NBACC),

operated by the Battelle National Biodefense Institute for the U.S.

Department of Homeland Security, is among the first customers to receive

the new PacBio RS system.

Nick Bergman, Ph.D., NBACC Genomics group leader, commented: “The PacBio RS

system is a major expansion of our sequencing repertoire here at NBACC,

and the long readlengths and flexibility in throughput give us a lot of

new options for characterizing microbial pathogens. We’re very excited

to start using it in a wide range of applications.”

The Wellcome Trust Sanger Institute was one of the eleven early access

sites for the PacBio RS that was recently upgraded to the

commercial hardware specifications. Harold Swerdlow, Ph.D., Head of

Sequencing Technology, commented: “To maintain our position at the

forefront of genomics, we explore new opportunities in genome

sequencing. We intend to use the PacBio RS to improve pathogen de

novo assemblies, to increase the coverage of sequence information

from organisms like the malaria parasite or Mycobacterium tuberculosis

at the extremes of AT/GC representation, and in the future, to explore

epigenetics via direct detection of methylated sites.”

Cold Spring Harbor Laboratory was also an early access customer, and is

also receiving one of the first new commercial systems. “We are

tremendously excited about the value of long reads for a variety of

projects ranging from understanding structural variation in the human

genome that contributes to disease, to de novo sequencing of

plant genomes,” said W. Richard McCombie, Ph.D.

Hugh Martin, Chairman and CEO of Pacific Biosciences, commented: “We

would like to thank our early access customers for their terrific

support and contributions to that program, and welcome our new customers

to the dawn of the era of third generation sequencing. We are incredibly

proud of the achievements that have led up to the development of a truly

transformative product that now has global demand from a number of

industry sectors, and a growing list of applications.”

For more information, please visit www.pacificbiosciences.com.

Photos, videos and animations are available at https://www.pacificbiosciences.com/news_and_events/mediakit.

You can also follow the company on Twitter www.twitter.com/PacBio.

About Pacific Biosciences

Pacific Biosciences’ mission is to transform the way humankind acquires,

processes and interprets data from living systems through the design,

development and commercialization of innovative tools for biological

research. The company has developed a novel approach to studying the

synthesis and regulation of DNA, RNA and proteins. Combining recent

advances in nanofabrication, biochemistry, molecular biology, surface

chemistry and optics, Pacific Biosciences has created a powerful

technology platform called single molecule, real-time, or SMRT™,

technology. SMRT technology enables real-time analysis of biomolecules

with single molecule resolution, which has the potential to transform

the understanding of biological systems by providing a window into these

systems that has not previously been open for scientific study.

This press release contains forward-looking statements. Forward-looking

statements may contain words such as “believe,” “may,” “estimate,”

“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of

these terms, or other similar expressions, and include the assumptions

that underlie such statements. These statements are subject to known and

unknown risks and uncertainties that could cause actual results to

differ materially from those expressed or implied by such statements,

including but not limited to risks discussed from time to time in

documents we have filed with the Securities and Exchange Commission,

including the risks identified under the section captioned “Risk

Factors” in our recently filed Annual Report on Form 10-K. All

forward-looking statements are based on management’s estimates,

projections and assumptions as of the date hereof. We undertake no

obligation to update any forward-looking statements.

Photos/Multimedia Gallery Available: https://www.businesswire.com/cgi-bin/mmg.cgi?eid=6695639&lang=en

For Pacific BiosciencesNicole Litchfield, 415-793-6468 (Media)
nicole@bioscribe.com
or
Pacific

BiosciencesTrevin Rard, 650-521-8450 (Investors)
ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media

Press Release

Pacific Biosciences Announces New Chief Financial Officer

Monday, September 14, 2020

Stay
Current

Visit our blog »